US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ryder

197.55

-2.3300-1.17%

Post-market: 197.550.00000.00%16:34 EDT

Volume:303.32K

Turnover:60.21M

Market Cap:7.75B

PE:16.55

High:201.20

Open:198.86

Low:197.16

Close:199.88

52wk High:230.39

52wk Low:125.54

Shares:39.21M

Float Shares:38.07M

Volume Ratio:0.77

T/O Rate:0.80%

Dividend:3.54

Dividend Rate:1.79%

EPS(TTM):11.94

EPS(LYR):11.94

ROE:16.24%

ROA:3.97%

PB:2.54

PE(LYR):16.55

Loading ...

Overview Company News Filings

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Press Release: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Press Release: Koss Corporation Drives Expansion Initiative with New Hire

Press Release: PTC COMPLETES DIVESTITURE OF KEPWARE AND THINGWORX BUSINESSES

Press Release: LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

Press Release: Byrna Technologies Appoints Robert Holmes as Vice President of New Product Development and R&D

Press Release: Planet Fitness Appoints Harmit Singh to Board of Directors

Press Release: Sotera Health Appoints Kenneth D. Krause to the Board of Directors

Press Release: NewtekOne, Inc. Declares Dividends on Common Stock and Series B Preferred Shares

Press Release: Duos Technologies Group Executes Definitive Agreement with Hydra Host

Press Release: bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath(R) Lung

Press Release: Bridgemarq Real Estate Services(R) Reports Annual Financial Results and Declares Monthly Dividend

Press Release: Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Press Release: Better Home & Finance Holding Company Announces Fourth Quarter 2025 Results

Press Release: Tenable Appoints Dino DiMarino as Chief Revenue Officer

Press Release: MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Press Release: Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/R/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"R","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"R\",,,,,undefined,":{"symbol":"R","market":"US","secType":"STK","nameCN":"Ryder","latestPrice":197.55,"timestamp":1774641600000,"preClose":199.88,"halted":0,"volume":303316,"hourTrading":{"tag":"盘后","latestPrice":197.55,"preClose":197.55,"latestTime":"16:34 EDT","volume":8005,"amount":1581387.75,"timestamp":1774643650985,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011656994196517832,"floatShares":38073300,"shares":39205715,"eps":11.937799,"marketStatus":"Market Closed","change":-2.33,"latestTime":"03-27 16:00:00 EDT","open":198.86,"high":201.2,"low":197.16,"amount":60209081.35112,"amplitude":0.020212,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.937799,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":-292968000000,"exchange":"NYSE","adjPreClose":199.88,"dividendRate":0.01792,"preHourTrading":{"tag":"盘前","latestPrice":200.47,"preClose":199.88,"latestTime":"05:08 EDT","volume":55,"amount":11040.64885,"timestamp":1774602536833,"change":0.59,"changeRate":0.002952,"amplitude":0.009606},"postHourTrading":{"tag":"盘后","latestPrice":197.55,"preClose":197.55,"latestTime":"16:34 EDT","volume":8005,"amount":1581387.75,"timestamp":1774643650985,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.771869,"impliedVol":0.4751,"impliedVolPercentile":0.9482},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"R\",,,,,undefined,":{"symbol":"R","floatShares":38073300,"roa":"3.97%","roe":"16.24%","lyrEps":11.937799,"volumeRatio":0.771869,"shares":39205715,"dividePrice":3.54,"high":201.2,"amplitude":0.020212,"preClose":199.88,"low":197.16,"week52Low":125.54,"pbRate":"2.54","psRate":"0.61","week52High":230.385,"institutionHeld":0.6659,"latestPrice":197.55,"eps":11.937799,"divideRate":0.01792,"volume":303316,"delay":0,"ttmEps":11.937799,"open":198.86,"prevYearClose":191.39,"prevWeekClose":191.78,"prevMonthClose":221.56,"prevQuarterClose":191.39,"fiveDayClose":191.78,"twentyDayClose":221.56,"sixtyDayClose":192.92,"earningDate":1776873600000,"earningTime":"盘前","dividendPayoutRate":0.28296082308697096,"dividendFrequency":"Q","dividendGrowthYears":10,"dividendGrowthRate":0.13157894736842102,"fiveYearAvgDividendRate":0.02341379230026732},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/R\",params:#limit:5,,,undefined,":[{"date":"2026-04-23","symbol":"R","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/03","expectedEps":2.31,"defaultRemindTime":1776931200000,"name":null,"time":"Pre-Market","dateTimestamp":1776916800000,"actualEps":null},{"date":"2026-02-17","symbol":"R","amount":0.91,"announcedDate":"2026-02-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-17","defaultRemindTime":1771338600000,"name":"瑞德系统","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-02-17","currency":"USD","dateTimestamp":1771304400000,"payDate":"2026-03-20"},{"market":"US","date":"2026-02-11","symbol":"R","fiscalQuarterEnding":"2025/12","expectedEps":3.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1770786000000,"reportTimeType":"pre","actualEps":3.59},{"date":"2025-11-17","symbol":"R","amount":0.91,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-17","defaultRemindTime":1763389800000,"name":"瑞德系统","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-11-17","currency":"USD","dateTimestamp":1763355600000,"payDate":"2025-12-19"},{"market":"US","date":"2025-10-23","symbol":"R","fiscalQuarterEnding":"2025/09","expectedEps":3.56,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1761192000000,"reportTimeType":"pre","actualEps":3.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"R\",market:\"US\",,,undefined,":[{"executeDate":"2016-05-19","recordDate":"2016-05-23","paymentDate":"2016-06-17","value":0.41,"currency":"USD"},{"executeDate":"2016-08-18","recordDate":"2016-08-22","paymentDate":"2016-09-16","value":0.44,"currency":"USD"},{"executeDate":"2016-11-17","recordDate":"2016-11-21","paymentDate":"2016-12-16","value":0.44,"currency":"USD"},{"executeDate":"2017-02-16","recordDate":"2017-02-21","paymentDate":"2017-03-17","value":0.44,"currency":"USD"},{"executeDate":"2017-05-18","recordDate":"2017-05-22","paymentDate":"2017-06-16","value":0.44,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"R\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.5455,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1770955200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/R\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"R","date":"2026-03-27","current":16.548277,"percent":0.873274,"low":-34.630262,"twenty":5.607776,"median":12.030258,"eighty":15.075828,"high":123.038,"avg":15.053786,"sd":23.199392,"marketCap":7836438314},"quantilePoints":[{"date":"2021-04-01","current":-33.933157,"twenty":-6.857111,"median":10.331083,"eighty":16.218817,"marketCap":4139845106},{"date":"2021-04-09","current":-34.04787,"twenty":-6.928836,"median":10.218314,"eighty":16.221611,"marketCap":4153840162},{"date":"2021-04-16","current":-34.32583,"twenty":-7.200998,"median":10.09827,"eighty":16.221611,"marketCap":4187751258},{"date":"2021-04-23","current":-32.988976,"twenty":-7.696196,"median":9.896378,"eighty":16.221611,"marketCap":4024655033},{"date":"2021-04-30","current":112.62731,"twenty":-7.755803,"median":9.861819,"eighty":16.210339,"marketCap":4301011698},{"date":"2021-05-07","current":123.038,"twenty":-7.755803,"median":9.861819,"eighty":16.210339,"marketCap":4698575154},{"date":"2021-05-14","current":120.103822,"twenty":-7.755803,"median":9.861819,"eighty":16.221611,"marketCap":4586524749},{"date":"2021-05-21","current":114.263678,"twenty":-7.755803,"median":9.861819,"eighty":16.281283,"marketCap":4363501347},{"date":"2021-05-28","current":115.378102,"twenty":-7.755803,"median":9.861819,"eighty":16.288377,"marketCap":4406058952},{"date":"2021-06-04","current":113.71352,"twenty":-7.755803,"median":9.861819,"eighty":16.288377,"marketCap":4342491896},{"date":"2021-06-11","current":112.034831,"twenty":-7.755803,"median":9.861819,"eighty":16.289543,"marketCap":4278386135},{"date":"2021-06-18","current":101.243262,"twenty":-7.755803,"median":9.861819,"eighty":16.414731,"marketCap":3866277674},{"date":"2021-06-25","current":106.166474,"twenty":-7.755803,"median":9.861819,"eighty":16.576042,"marketCap":4054285325},{"date":"2021-07-02","current":104.699385,"twenty":-7.755803,"median":9.861819,"eighty":16.620493,"marketCap":3998260123},{"date":"2021-07-09","current":104.191547,"twenty":-7.755803,"median":9.861819,"eighty":16.682515,"marketCap":3978866783},{"date":"2021-07-16","current":100.086518,"twenty":-7.755803,"median":9.861819,"eighty":16.729366,"marketCap":3822103957},{"date":"2021-07-23","current":103.556748,"twenty":-7.755803,"median":9.861819,"eighty":16.762384,"marketCap":3954625109},{"date":"2021-07-30","current":15.665589,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4094859563},{"date":"2021-08-06","current":15.879538,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4150784106},{"date":"2021-08-13","current":16.330065,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4268548288},{"date":"2021-08-20","current":15.305578,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4000755765},{"date":"2021-08-27","current":16.714761,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4369104918},{"date":"2021-09-03","current":16.395895,"twenty":-7.751218,"median":9.87728,"eighty":16.767739,"marketCap":4285755840},{"date":"2021-09-10","current":16.046171,"twenty":-7.751218,"median":9.87728,"eighty":16.767739,"marketCap":4194340722},{"date":"2021-09-17","current":16.161374,"twenty":-7.751218,"median":9.87728,"eighty":16.767739,"marketCap":4224453937},{"date":"2021-09-24","current":16.916367,"twenty":-7.751218,"median":9.87728,"eighty":16.7724,"marketCap":4421803045},{"date":"2021-10-01","current":17.126202,"twenty":-7.751218,"median":9.87728,"eighty":16.824146,"marketCap":4476652116},{"date":"2021-10-08","current":17.115916,"twenty":-7.751218,"median":9.87728,"eighty":16.86858,"marketCap":4473963436},{"date":"2021-10-15","current":17.229062,"twenty":-7.751218,"median":9.87728,"eighty":16.897726,"marketCap":4503538916},{"date":"2021-10-22","current":18.296749,"twenty":-7.751218,"median":9.87728,"eighty":16.957122,"marketCap":4782623895},{"date":"2021-10-29","current":12.544258,"twenty":-7.746632,"median":9.89274,"eighty":16.972991,"marketCap":4561242691},{"date":"2021-11-05","current":12.858787,"twenty":-7.746632,"median":9.89274,"eighty":16.972991,"marketCap":4675609342},{"date":"2021-11-12","current":12.99464,"twenty":-7.746632,"median":9.89274,"eighty":16.946201,"marketCap":4725007144},{"date":"2021-11-19","current":12.432031,"twenty":-7.746632,"median":9.89274,"eighty":16.881013,"marketCap":4520435811},{"date":"2021-11-26","current":12.601848,"twenty":-7.746632,"median":9.89274,"eighty":16.848905,"marketCap":4582183064},{"date":"2021-12-03","current":11.712896,"twenty":-7.746632,"median":9.89274,"eighty":16.823699,"marketCap":4258949621},{"date":"2021-12-10","current":11.980172,"twenty":-7.746632,"median":9.89274,"eighty":16.771738,"marketCap":4356134427},{"date":"2021-12-17","current":11.548987,"twenty":-7.746632,"median":9.89274,"eighty":16.734025,"marketCap":4199350099},{"date":"2021-12-23","current":11.717326,"twenty":-7.746632,"median":9.89274,"eighty":16.724457,"marketCap":4260560419},{"date":"2021-12-31","current":12.172139,"twenty":-7.746632,"median":9.89274,"eighty":16.688297,"marketCap":4425935669},{"date":"2022-01-07","current":11.528313,"twenty":-7.742047,"median":9.894559,"eighty":16.645088,"marketCap":4191833042},{"date":"2022-01-14","current":11.66269,"twenty":-7.742047,"median":9.894559,"eighty":16.569237,"marketCap":4240693911},{"date":"2022-01-21","current":11.074978,"twenty":-7.742047,"median":9.894559,"eighty":16.518713,"marketCap":4026994725},{"date":"2022-01-28","current":10.665942,"twenty":-7.742047,"median":9.894559,"eighty":16.390958,"marketCap":3878264386},{"date":"2022-02-04","current":10.595062,"twenty":-7.742047,"median":9.894559,"eighty":16.292436,"marketCap":3852491620},{"date":"2022-02-11","current":10.866768,"twenty":-7.742047,"median":9.894559,"eighty":16.266226,"marketCap":3951287224},{"date":"2022-02-18","current":8.156002,"twenty":-7.742047,"median":9.819077,"eighty":16.167134,"marketCap":4232965038},{"date":"2022-02-25","current":8.041976,"twenty":-7.742047,"median":9.683571,"eighty":16.061394,"marketCap":4173785303},{"date":"2022-03-04","current":8.192283,"twenty":-7.742047,"median":9.408015,"eighty":15.879949,"marketCap":4251794953},{"date":"2022-03-11","current":8.208869,"twenty":-7.742047,"median":8.965509,"eighty":15.706321,"marketCap":4260402915},{"date":"2022-03-18","current":8.2995,"twenty":-7.742047,"median":8.822833,"eighty":15.524465,"marketCap":4307440377},{"date":"2022-03-25","current":7.957709,"twenty":-7.742047,"median":8.777473,"eighty":15.400744,"marketCap":4130051128},{"date":"2022-04-01","current":7.287918,"twenty":-7.742047,"median":8.581191,"eighty":15.306166,"marketCap":3782429545},{"date":"2022-04-08","current":6.216252,"twenty":-7.742047,"median":8.486348,"eighty":15.123407,"marketCap":3226235013},{"date":"2022-04-14","current":6.305886,"twenty":-7.742047,"median":8.400577,"eighty":15.064281,"marketCap":3272754960},{"date":"2022-04-22","current":6.644722,"twenty":-7.742047,"median":8.337941,"eighty":15.019858,"marketCap":3448610584},{"date":"2022-04-29","current":5.552093,"twenty":-7.742047,"median":8.266103,"eighty":15.01151,"marketCap":3574453932},{"date":"2022-05-06","current":5.903169,"twenty":-7.742047,"median":8.228212,"eighty":15.01151,"marketCap":3800478057},{"date":"2022-05-13","current":6.644243,"twenty":-7.742047,"median":8.178807,"eighty":15.01151,"marketCap":4277583282},{"date":"2022-05-20","current":6.306669,"twenty":-7.742047,"median":8.111521,"eighty":15.01151,"marketCap":4060252392},{"date":"2022-05-27","current":6.362269,"twenty":-7.742047,"median":8.052823,"eighty":15.01151,"marketCap":4096048068},{"date":"2022-06-03","current":6.481413,"twenty":-7.742047,"median":8.032181,"eighty":15.01151,"marketCap":4172753088},{"date":"2022-06-10","current":6.150194,"twenty":-7.742047,"median":8.016693,"eighty":15.01151,"marketCap":3959513132},{"date":"2022-06-17","current":5.747488,"twenty":-7.742047,"median":7.956055,"eighty":15.01151,"marketCap":3700250164},{"date":"2022-06-24","current":5.650585,"twenty":-7.746632,"median":7.945333,"eighty":15.013418,"marketCap":3637863415},{"date":"2022-07-01","current":5.726042,"twenty":-7.746632,"median":7.897499,"eighty":15.013418,"marketCap":3686443261},{"date":"2022-07-08","current":5.746694,"twenty":-7.746632,"median":7.835691,"eighty":15.013418,"marketCap":3699738798},{"date":"2022-07-15","current":5.766551,"twenty":-7.746632,"median":7.772142,"eighty":15.013418,"marketCap":3712522968},{"date":"2022-07-22","current":5.926204,"twenty":-7.746632,"median":7.442255,"eighty":15.013418,"marketCap":3815307694},{"date":"2022-07-29","current":5.461894,"twenty":-7.746632,"median":6.699881,"eighty":15.013418,"marketCap":4009565771},{"date":"2022-08-05","current":5.457013,"twenty":-7.746632,"median":6.644722,"eighty":15.013418,"marketCap":4005982145},{"date":"2022-08-12","current":5.788269,"twenty":-7.746632,"median":6.481413,"eighty":15.013418,"marketCap":4249156780},{"date":"2022-08-19","current":5.654372,"twenty":-7.746632,"median":6.388625,"eighty":15.013418,"marketCap":4150863032},{"date":"2022-08-26","current":5.604858,"twenty":-7.746632,"median":6.320172,"eighty":15.013418,"marketCap":4114514824},{"date":"2022-09-02","current":5.186429,"twenty":-7.746632,"median":6.234388,"eighty":15.013418,"marketCap":3807346864},{"date":"2022-09-09","current":5.427723,"twenty":-7.746632,"median":6.204433,"eighty":15.013418,"marketCap":3984480387},{"date":"2022-09-16","current":4.997438,"twenty":-7.746632,"median":6.039787,"eighty":15.013418,"marketCap":3668609335},{"date":"2022-09-23","current":4.66409,"twenty":-7.746632,"median":5.934147,"eighty":15.013418,"marketCap":3423898860},{"date":"2022-09-30","current":5.264535,"twenty":-7.746632,"median":5.891255,"eighty":14.984817,"marketCap":3864684883},{"date":"2022-10-07","current":5.515593,"twenty":-7.746632,"median":5.79038,"eighty":14.962577,"marketCap":4048985659},{"date":"2022-10-14","current":5.330787,"twenty":-7.746632,"median":5.747488,"eighty":14.951585,"marketCap":3913319810},{"date":"2022-10-21","current":5.177363,"twenty":-7.746632,"median":5.716511,"eighty":14.921021,"marketCap":3800691558},{"date":"2022-10-28","current":4.875682,"twenty":-7.746632,"median":5.696654,"eighty":14.896597,"marketCap":4105514216},{"date":"2022-11-04","current":4.97415,"twenty":-7.746632,"median":5.677591,"eighty":14.776301,"marketCap":4188428518},{"date":"2022-11-11","current":5.292233,"twenty":-7.746632,"median":5.663293,"eighty":14.711779,"marketCap":4456266838},{"date":"2022-11-18","current":5.380557,"twenty":-7.746632,"median":5.641848,"eighty":14.711779,"marketCap":4530638454},{"date":"2022-11-25","current":5.732059,"twenty":-7.746632,"median":5.632098,"eighty":14.711779,"marketCap":4826617386},{"date":"2022-12-02","current":5.390702,"twenty":-7.746632,"median":5.616713,"eighty":13.024764,"marketCap":4539181140},{"date":"2022-12-09","current":5.00757,"twenty":-7.746632,"median":5.60073,"eighty":12.852585,"marketCap":4216569129},{"date":"2022-12-16","current":5.043377,"twenty":-7.746632,"median":5.579284,"eighty":12.794995,"marketCap":4246719784},{"date":"2022-12-23","current":5.054119,"twenty":-7.746632,"median":5.556738,"eighty":12.683064,"marketCap":4255764981},{"date":"2022-12-30","current":4.987279,"twenty":-7.746632,"median":5.542093,"eighty":12.55727,"marketCap":4199483758},{"date":"2023-01-06","current":4.977134,"twenty":-7.746632,"median":5.530238,"eighty":12.411068,"marketCap":4190941072},{"date":"2023-01-13","current":5.452767,"twenty":-7.746632,"median":5.515593,"eighty":12.297336,"marketCap":4591442276},{"date":"2023-01-20","current":5.542284,"twenty":-7.746632,"median":5.512803,"eighty":12.262396,"marketCap":4666818914},{"date":"2023-01-27","current":5.635978,"twenty":-7.746632,"median":5.512803,"eighty":12.179012,"marketCap":4745713128},{"date":"2023-02-03","current":5.849625,"twenty":-7.746632,"median":5.504687,"eighty":12.076451,"marketCap":4925612037},{"date":"2023-02-10","current":5.754737,"twenty":-7.746632,"median":5.504687,"eighty":12.026911,"marketCap":4845712801},{"date":"2023-02-17","current":5.263255,"twenty":-7.746632,"median":5.498719,"eighty":11.969767,"marketCap":4563242372},{"date":"2023-02-24","current":5.148999,"twenty":-7.746632,"median":5.492154,"eighty":11.969767,"marketCap":4464182332},{"date":"2023-03-03","current":5.301697,"twenty":-7.746632,"median":5.485925,"eighty":11.969767,"marketCap":4596570983},{"date":"2023-03-10","current":4.857486,"twenty":-7.746632,"median":5.474851,"eighty":11.969767,"marketCap":4211440363},{"date":"2023-03-17","current":4.455455,"twenty":-7.746632,"median":5.452767,"eighty":11.969767,"marketCap":3862879398},{"date":"2023-03-24","current":4.499409,"twenty":-7.746632,"median":5.427723,"eighty":11.969767,"marketCap":3900987688},{"date":"2023-03-31","current":4.783503,"twenty":-7.742047,"median":5.424379,"eighty":11.966298,"marketCap":4147297371},{"date":"2023-04-06","current":4.522458,"twenty":-7.742047,"median":5.424379,"eighty":11.966298,"marketCap":3920971304},{"date":"2023-04-14","current":4.579277,"twenty":-7.746632,"median":5.427723,"eighty":11.969767,"marketCap":3970233240},{"date":"2023-04-21","current":4.639312,"twenty":-7.746632,"median":5.394248,"eighty":11.969767,"marketCap":4022283588},{"date":"2023-04-28","current":4.360113,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3618893391},{"date":"2023-05-05","current":4.456979,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3699292590},{"date":"2023-05-12","current":4.543916,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3771449940},{"date":"2023-05-19","current":4.544476,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3771914863},{"date":"2023-05-26","current":4.48342,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3721238329},{"date":"2023-06-02","current":4.478378,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3717054028},{"date":"2023-06-09","current":4.659306,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3867223940},{"date":"2023-06-16","current":4.628498,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3841653212},{"date":"2023-06-23","current":4.605532,"twenty":-7.751218,"median":5.393551,"eighty":11.973235,"marketCap":3822591397},{"date":"2023-06-30","current":4.710279,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":3909531872},{"date":"2023-07-07","current":4.670509,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":3876522387},{"date":"2023-07-14","current":4.972428,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":4127115523},{"date":"2023-07-21","current":5.1696,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":4290768183},{"date":"2023-07-28","current":7.905694,"twenty":-7.755803,"median":5.397863,"eighty":11.976704,"marketCap":4529962569},{"date":"2023-08-04","current":7.943832,"twenty":-7.755803,"median":5.452767,"eighty":11.976704,"marketCap":4551815654},{"date":"2023-08-11","current":8.064602,"twenty":-7.755803,"median":5.493974,"eighty":11.976704,"marketCap":4621017093},{"date":"2023-08-18","current":7.684017,"twenty":-7.755803,"median":5.519009,"eighty":11.976704,"marketCap":4402941508},{"date":"2023-08-25","current":7.629988,"twenty":-7.755803,"median":5.540699,"eighty":11.976704,"marketCap":4371982969},{"date":"2023-09-01","current":8.001039,"twenty":-7.755803,"median":5.556738,"eighty":11.976704,"marketCap":4584595283},{"date":"2023-09-08","current":7.796047,"twenty":-7.755803,"median":5.572744,"eighty":11.976704,"marketCap":4467134947},{"date":"2023-09-15","current":8.072548,"twenty":-7.755803,"median":5.598162,"eighty":11.976704,"marketCap":4625569819},{"date":"2023-09-22","current":8.255292,"twenty":-7.755803,"median":5.622292,"eighty":11.976704,"marketCap":4730282521},{"date":"2023-09-29","current":8.464257,"twenty":-7.755803,"median":5.641349,"eighty":11.976704,"marketCap":4850019220},{"date":"2023-10-06","current":7.874707,"twenty":-7.755803,"median":5.654372,"eighty":11.976704,"marketCap":4512206936},{"date":"2023-10-13","current":8.166304,"twenty":-7.755803,"median":5.677385,"eighty":11.976704,"marketCap":4679291988},{"date":"2023-10-20","current":7.969257,"twenty":-7.755803,"median":5.687122,"eighty":11.976704,"marketCap":4566384378},{"date":"2023-10-27","current":8.466638,"twenty":-7.81017,"median":5.70583,"eighty":11.984307,"marketCap":4131719492},{"date":"2023-11-03","current":8.900778,"twenty":-7.81017,"median":5.736104,"eighty":11.984307,"marketCap":4343579814},{"date":"2023-11-10","current":9.098775,"twenty":-7.81017,"median":5.748824,"eighty":11.984307,"marketCap":4440202303},{"date":"2023-11-17","current":9.541998,"twenty":-7.81017,"median":5.774024,"eighty":11.984307,"marketCap":4656494849},{"date":"2023-11-24","current":9.76815,"twenty":-7.81017,"median":5.792649,"eighty":11.984307,"marketCap":4766857234},{"date":"2023-12-01","current":9.730912,"twenty":-7.81017,"median":5.832915,"eighty":11.984307,"marketCap":4748685115},{"date":"2023-12-08","current":9.643721,"twenty":-7.785279,"median":5.902141,"eighty":11.982239,"marketCap":4706135761},{"date":"2023-12-15","current":10.11964,"twenty":-7.785279,"median":5.934147,"eighty":11.982239,"marketCap":4938384315},{"date":"2023-12-22","current":10.650962,"twenty":-7.785279,"median":6.039787,"eighty":11.982239,"marketCap":5197669436},{"date":"2023-12-29","current":10.469313,"twenty":-7.81017,"median":6.186334,"eighty":11.984307,"marketCap":5109024950},{"date":"2024-01-05","current":10.161419,"twenty":-7.835061,"median":6.212148,"eighty":11.986374,"marketCap":4958772546},{"date":"2024-01-12","current":10.035173,"twenty":-7.835061,"median":6.306669,"eighty":11.986374,"marketCap":4897164629},{"date":"2024-01-19","current":10.137805,"twenty":-7.859952,"median":6.350752,"eighty":11.988442,"marketCap":4947248763},{"date":"2024-01-26","current":10.437525,"twenty":-7.835061,"median":6.413898,"eighty":11.986374,"marketCap":5093512165},{"date":"2024-02-02","current":10.526533,"twenty":-7.835061,"median":6.548928,"eighty":11.986374,"marketCap":5136947963},{"date":"2024-02-09","current":10.603733,"twenty":-7.835061,"median":6.662452,"eighty":11.986374,"marketCap":5174621870},{"date":"2024-02-16","current":11.958272,"twenty":-7.835061,"median":6.699881,"eighty":11.992994,"marketCap":4855058498},{"date":"2024-02-23","current":12.181128,"twenty":-7.835061,"median":6.699881,"eighty":12.003352,"marketCap":4945538144},{"date":"2024-03-01","current":12.341207,"twenty":-7.81017,"median":6.732825,"eighty":12.070758,"marketCap":5010530121},{"date":"2024-03-08","current":12.549959,"twenty":-7.81017,"median":6.732825,"eighty":12.1283,"marketCap":5095283172},{"date":"2024-03-15","current":12.315273,"twenty":-7.81017,"median":6.732825,"eighty":12.192966,"marketCap":5000001022},{"date":"2024-03-22","current":12.709973,"twenty":-7.81017,"median":6.732825,"eighty":12.252055,"marketCap":5160248952},{"date":"2024-03-28","current":12.9324,"twenty":-7.81017,"median":6.732825,"eighty":12.27243,"marketCap":5250554416},{"date":"2024-04-05","current":12.824457,"twenty":-7.835061,"median":6.699881,"eighty":12.310529,"marketCap":5206729706},{"date":"2024-04-12","current":12.753586,"twenty":-7.835061,"median":6.699881,"eighty":12.337386,"marketCap":5177955906},{"date":"2024-04-19","current":11.685063,"twenty":-7.835061,"median":6.699881,"eighty":12.340342,"marketCap":4744135543},{"date":"2024-04-26","current":15.244202,"twenty":-7.81017,"median":6.732825,"eighty":12.359817,"marketCap":5365959126},{"date":"2024-05-03","current":15.528093,"twenty":-7.81017,"median":6.732825,"eighty":12.422817,"marketCap":5465888775},{"date":"2024-05-10","current":15.863035,"twenty":-7.81017,"median":6.732825,"eighty":12.516984,"marketCap":5583788228},{"date":"2024-05-17","current":15.561712,"twenty":-7.81017,"median":6.732825,"eighty":12.565399,"marketCap":5477722549},{"date":"2024-05-24","current":14.992685,"twenty":-7.81017,"median":6.732825,"eighty":12.683064,"marketCap":5277424965},{"date":"2024-05-31","current":15.007626,"twenty":-7.81017,"median":6.732825,"eighty":12.75491,"marketCap":5282684420},{"date":"2024-06-07","current":14.981478,"twenty":-7.81017,"median":6.732825,"eighty":12.826376,"marketCap":5273480373},{"date":"2024-06-14","current":14.965292,"twenty":-7.835061,"median":6.699881,"eighty":12.854653,"marketCap":5267782630},{"date":"2024-06-21","current":15.053696,"twenty":-7.859952,"median":6.696926,"eighty":12.903973,"marketCap":5298901073},{"date":"2024-06-28","current":15.257899,"twenty":-7.926764,"median":6.670331,"eighty":12.934444,"marketCap":5370780294},{"date":"2024-07-05","current":15.332607,"twenty":-7.926764,"median":6.670331,"eighty":13.078605,"marketCap":5397077570},{"date":"2024-07-12","current":15.560467,"twenty":-7.926764,"median":6.670331,"eighty":14.67393,"marketCap":5477284261},{"date":"2024-07-15","current":16.031128,"twenty":-7.926764,"median":6.670331,"eighty":14.798941,"marketCap":5642957098},{"date":"2024-08-02","current":12.046137,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5986929872},{"date":"2024-08-09","current":11.643786,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5786961567},{"date":"2024-08-16","current":11.960789,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5944512353},{"date":"2024-08-23","current":12.044395,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5986064208},{"date":"2024-08-30","current":12.267342,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6096869157},{"date":"2024-09-06","current":11.844961,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5886945719},{"date":"2024-09-13","current":11.837994,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5883483065},{"date":"2024-09-20","current":12.877836,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6400284270},{"date":"2024-09-27","current":12.605247,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6264807907},{"date":"2024-10-04","current":12.39275,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6159196940},{"date":"2024-10-11","current":12.762878,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6343150468},{"date":"2024-10-18","current":12.754684,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6339078000},{"date":"2024-10-25","current":12.285395,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5872418977},{"date":"2024-10-31","current":13.170128,"twenty":-8.0879,"median":6.543636,"eighty":14.807159,"marketCap":6295321107},{"date":"2024-11-08","current":14.050437,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6716108726},{"date":"2024-11-15","current":14.657363,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":7006219587},{"date":"2024-11-22","current":14.262772,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6817605237},{"date":"2024-11-29","current":14.937823,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":7140279562},{"date":"2024-12-06","current":14.566236,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6962660668},{"date":"2024-12-13","current":14.75026,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":7050624311},{"date":"2024-12-20","current":13.771746,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6582894555},{"date":"2024-12-27","current":14.153066,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6765165373},{"date":"2025-01-03","current":13.844294,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6617572530},{"date":"2025-01-10","current":14.016817,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":6700038445},{"date":"2025-01-17","current":14.647631,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":7001567664},{"date":"2025-01-24","current":14.644977,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":7000298957},{"date":"2025-01-31","current":14.36894,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":6868353493},{"date":"2025-02-07","current":13.879683,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":6634488615},{"date":"2025-02-14","current":13.862207,"twenty":-8.03386,"median":6.543636,"eighty":13.316137,"marketCap":6778619352},{"date":"2025-02-21","current":14.292524,"twenty":-7.746632,"median":6.652028,"eighty":13.787317,"marketCap":6989043992},{"date":"2025-02-28","current":13.739137,"twenty":-7.30351,"median":6.732825,"eighty":13.829167,"marketCap":6718437905},{"date":"2025-03-07","current":13.320009,"twenty":-6.938007,"median":7.55689,"eighty":13.830759,"marketCap":6513484306},{"date":"2025-03-14","current":11.737306,"twenty":-6.885604,"median":7.691962,"eighty":13.830759,"marketCap":5739542480},{"date":"2025-03-21","current":11.989848,"twenty":-6.794229,"median":7.780156,"eighty":13.830759,"marketCap":5863035670},{"date":"2025-03-28","current":12.289466,"twenty":-6.704491,"median":7.818294,"eighty":13.830759,"marketCap":6009548949},{"date":"2025-04-04","current":11.830222,"twenty":-6.612788,"median":7.905144,"eighty":13.830759,"marketCap":5784978738},{"date":"2025-04-11","current":11.83449,"twenty":-6.460167,"median":7.944627,"eighty":13.830628,"marketCap":5787065822},{"date":"2025-04-17","current":11.790103,"twenty":-6.392044,"median":7.965682,"eighty":13.830628,"marketCap":5765360151},{"date":"2025-04-25","current":11.457658,"twenty":-6.145958,"median":8.001039,"eighty":13.830759,"marketCap":5751744390},{"date":"2025-05-02","current":11.438717,"twenty":-5.907983,"median":8.021733,"eighty":13.830759,"marketCap":5742236008},{"date":"2025-05-09","current":12.069535,"twenty":4.422322,"median":8.052268,"eighty":13.830759,"marketCap":6058906475},{"date":"2025-05-16","current":12.972115,"twenty":4.465495,"median":8.071753,"eighty":13.830759,"marketCap":6512001555},{"date":"2025-05-23","current":12.379179,"twenty":4.482002,"median":8.092411,"eighty":13.830759,"marketCap":6214347853},{"date":"2025-05-30","current":12.411296,"twenty":4.504369,"median":8.124987,"eighty":13.830759,"marketCap":6230470762},{"date":"2025-06-06","current":12.205416,"twenty":4.52924,"median":8.150819,"eighty":13.830759,"marketCap":6127118782},{"date":"2025-06-13","current":12.324003,"twenty":4.54414,"median":8.183784,"eighty":13.830759,"marketCap":6186649522},{"date":"2025-06-20","current":12.475531,"twenty":4.557695,"median":8.223114,"eighty":13.830891,"marketCap":6262716580},{"date":"2025-06-27","current":13.078349,"twenty":4.57381,"median":8.253849,"eighty":13.830891,"marketCap":6565331177},{"date":"2025-07-03","current":14.129163,"twenty":4.586262,"median":8.30557,"eighty":13.858624,"marketCap":7092839683},{"date":"2025-07-11","current":14.494806,"twenty":4.600504,"median":8.337941,"eighty":13.890852,"marketCap":7276392799},{"date":"2025-07-18","current":14.164574,"twenty":4.608827,"median":8.434859,"eighty":13.981782,"marketCap":7110616224},{"date":"2025-07-25","current":14.307417,"twenty":4.625011,"median":8.858999,"eighty":14.002789,"marketCap":7225245354},{"date":"2025-08-01","current":14.354265,"twenty":4.633104,"median":9.160989,"eighty":14.049906,"marketCap":7248903923},{"date":"2025-08-08","current":14.19918,"twenty":4.650193,"median":9.572878,"eighty":14.097858,"marketCap":7170585902},{"date":"2025-08-15","current":14.709669,"twenty":4.666003,"median":9.666427,"eighty":14.127845,"marketCap":7428382721},{"date":"2025-08-22","current":14.573161,"twenty":4.709831,"median":9.71638,"eighty":14.151964,"marketCap":7359446547},{"date":"2025-08-29","current":15.114344,"twenty":4.783503,"median":9.76815,"eighty":14.198571,"marketCap":7632743808},{"date":"2025-09-05","current":15.23712,"twenty":4.812786,"median":9.833544,"eighty":14.238885,"marketCap":7694745575},{"date":"2025-09-12","current":15.312239,"twenty":4.861125,"median":10.041985,"eighty":14.314092,"marketCap":7732680866},{"date":"2025-09-19","current":14.993992,"twenty":4.931659,"median":10.156878,"eighty":14.354103,"marketCap":7571965760},{"date":"2025-09-26","current":14.909987,"twenty":4.960305,"median":10.2309,"eighty":14.420027,"marketCap":7529543499},{"date":"2025-10-03","current":15.384936,"twenty":4.977731,"median":10.32899,"eighty":14.468748,"marketCap":7769392438},{"date":"2025-10-10","current":14.883332,"twenty":4.997531,"median":10.44025,"eighty":14.503112,"marketCap":7516082589},{"date":"2025-10-17","current":14.752479,"twenty":5.035793,"median":10.493382,"eighty":14.525335,"marketCap":7450001759},{"date":"2025-10-24","current":12.89259,"twenty":5.054716,"median":10.599398,"eighty":14.539205,"marketCap":6472080000},{"date":"2025-10-31","current":13.625069,"twenty":5.097183,"median":10.658452,"eighty":14.539205,"marketCap":6839784859},{"date":"2025-11-07","current":13.479489,"twenty":5.12209,"median":10.73345,"eighty":14.539205,"marketCap":6766703333},{"date":"2025-11-14","current":13.617026,"twenty":5.133219,"median":10.893348,"eighty":14.539205,"marketCap":6835747206},{"date":"2025-11-21","current":13.070093,"twenty":5.152815,"median":11.090483,"eighty":14.539205,"marketCap":6561186775},{"date":"2025-11-28","current":13.873602,"twenty":5.177781,"median":11.196803,"eighty":14.539205,"marketCap":6964548349},{"date":"2025-12-05","current":14.478446,"twenty":5.19145,"median":11.302112,"eighty":14.539205,"marketCap":7268179885},{"date":"2025-12-12","current":15.927014,"twenty":5.207168,"median":11.404144,"eighty":14.629582,"marketCap":7995361262},{"date":"2025-12-19","current":15.296433,"twenty":5.254517,"median":11.451225,"eighty":14.655417,"marketCap":7678809236},{"date":"2025-12-26","current":15.906907,"twenty":5.265027,"median":11.491086,"eighty":14.698585,"marketCap":7985267129},{"date":"2026-01-02","current":15.393755,"twenty":5.303504,"median":11.530528,"eighty":14.710447,"marketCap":7727664842},{"date":"2026-01-09","current":15.285172,"twenty":5.326043,"median":11.631919,"eighty":14.756356,"marketCap":7673156521},{"date":"2026-01-16","current":15.624593,"twenty":5.335095,"median":11.673876,"eighty":14.821626,"marketCap":7843545494},{"date":"2026-01-23","current":15.790281,"twenty":5.381631,"median":11.714373,"eighty":14.842245,"marketCap":7926721154},{"date":"2026-01-30","current":15.476599,"twenty":5.397735,"median":11.740952,"eighty":14.909825,"marketCap":7769252672},{"date":"2026-02-06","current":17.236437,"twenty":5.43372,"median":11.783021,"eighty":14.940109,"marketCap":8652691236},{"date":"2026-02-13","current":16.435376,"twenty":5.467946,"median":11.830222,"eighty":14.977245,"marketCap":8201252704},{"date":"2026-02-20","current":17.329797,"twenty":5.50631,"median":11.845396,"eighty":14.992461,"marketCap":8647568653},{"date":"2026-02-27","current":17.630044,"twenty":5.529122,"median":11.868324,"eighty":15.006515,"marketCap":8797392028},{"date":"2026-03-06","current":16.622636,"twenty":5.543836,"median":11.926274,"eighty":15.027061,"marketCap":8294695177},{"date":"2026-03-13","current":14.692322,"twenty":5.566305,"median":11.961621,"eighty":15.051953,"marketCap":7331468705},{"date":"2026-03-20","current":15.122092,"twenty":5.582426,"median":12.000539,"eighty":15.06114,"marketCap":7545923966},{"date":"2026-03-27","current":15.704285,"twenty":5.607776,"median":12.030258,"eighty":15.075828,"marketCap":7836438314}],"updateTime":1774733720265},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"R\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620996484","title":"Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620996484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620996484?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:07","pubTimestamp":1773691620,"startTime":"0","endTime":"0","summary":"-- Lead program VMT-<ALPHA>-NET in neuroendocrine tumors continues to. demonstrate a favorable tolerability profile with durable disease control. and deepening of tumor response with longer follow-up, as reported at. -- VMT-<ALPHA>-NET study on track to achieve nearly one year of follow-up in. all 46 patients in Cohort 2 by mid-2026; analysis to inform patient. -- Data across all dose levels in the VMT-<ALPHA>-NET program provide. development optionality and support the build-out of a robust clinical. evidence package for submission for presentation to more medical. -- Clinical updates for all three clinical programs are expected to be. submitted for presentation at medical conferences throughout 2026. -- Cash, cash equivalents and short-term investments of approximately $145M. as of December 31, 2025, together with subsequent equity offering (net. proceeds of $164 million), expected to be sufficient to fund current. planned clinical milestones and operational investments into late 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4116","BK4588","DCO","IE00B66KJ199.SGD","BK4110","LU2286300806.USD","LU2065171311.SGD","CATX","BK4187","BK4144","LU2065171402.SGD","NETG","RPT","BK4554","IE0031619046.USD","BK4231","SMC","BK4139","BK4022","BK4613","NET","LU2065169927.USD","BK4080","LU0566484027.USD","LU1559883803.SGD","BK4548","BK4585","IE00B19Z4B17.USD","BK4232","NETX","R","LU2065170008.USD","IE00B7SZL793.SGD","BK4560","BK4607"],"gpt_icon":0},{"id":"2620499642","title":"Press Release: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499642","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499642?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:05","pubTimestamp":1773691500,"startTime":"0","endTime":"0","summary":"Atara delivers significant operational efficiencies and extends cash runway through year-end 2026. A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA. Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus  T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates.A Type A meeting with the U.S. Food and Drug Administration  has been scheduled for our partner Pierre Fabre Pharmaceuticals to discuss the issues raised by the FDA in the Complete Response Letter received in January 2026. We anticipate providing a regulatory update in the second quarter.million for the fourth quarter and fiscal year 2025, as compared to $24.5. and fiscal year 2025, respectively, as compared to a net loss of . million, or  per share, and  million, or  per sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","TM","BK4588","ATRA","R","03160","BK4139","PRGS","BK4099","BK4097","BK4555","BK4585","BK4604","LU2065732104.USD","BK4022"],"gpt_icon":0},{"id":"2620870499","title":"Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620870499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620870499?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer  is actively enrolling and remains on track for. -- Positive results from the investigator-sponsored study of FG-3246 in. combination with enzalutamide in patients with mCRPC, further validating. key Phase 2 monotherapy design elements, were presented at the 2026 ASCO. \"The encouraging results from the investigator-sponsored combination trial of FG-3246 with enzalutamide provide us with valuable insights and reinforce key design elements in our Phase 2 monotherapy study,\" said Thane Wettig, Chief Executive Officer of Kyntra Bio. \"Our Phase 2 monotherapy trial of FG-3246 is progressing as planned, with interim results expected in the second half of 2026. Additionally, we have submitted the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and expect feedback from the FDA shortly, with the intention to start a Phase 3 trial in the second half of 2026. With","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","R","BK4099","LU0128525689.USD","LU1267930490.SGD","LU0052756011.USD","LU1267930227.SGD","LU0310800965.SGD","BK4080","DD","BK4604","KYNB","BK4588","BK4109","BK4504","BK4022","TM","BK4139","03160","BK4585","BK4231","ADC","BK4555","LU0310799852.SGD","BK4232","LU0211328371.USD","LU0211327993.USD"],"gpt_icon":0},{"id":"2620499862","title":"Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499862","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499862?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:01","pubTimestamp":1773691260,"startTime":"0","endTime":"0","summary":"NEWARK, N.J., March 16, 2026  -- Rafael Holdings, Inc.  today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.\"We remain pleased with the progress of our pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee  recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol Cyclo could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,\" said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.\"We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year,\" said Joshua Fine, Chief Operating Officer of Rafael Holdings.Research and development expenses were $12.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4555","R","RFL","BK4232","BK4099","03160","BK4205","BK4585","BK4588","TM","BK4233","BK4007","BK4022"],"gpt_icon":0},{"id":"2619546524","title":"Press Release: Koss Corporation Drives Expansion Initiative with New Hire","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546524","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619546524?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:15","pubTimestamp":1773666900,"startTime":"0","endTime":"0","summary":"MILWAUKEE, March 16, 2026  -- Koss Corporation  , the U.S. based high-fidelity headphone company, has announced the addition of Megan Brobson as Director of Acquisitions and Corporate Development.\"We intend to use the strength of our balance sheet to add solid, well-managed companies to our portfolio,\" Michael J. Koss, Chairman and CEO said today. \"Our first step in this process is the addition of new talent.\". \"Megan brings the optimal skill set and fresh market experience for this new initiative,\" Michael J. Koss Jr., Executive Vice President said. \"We are pleased and excited to have her join the team.\". Koss Corporation markets a complete line of high-fidelity headphones, wireless Blu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4078","BK4547","KOSS","BK4232","R","BK4022"],"gpt_icon":0},{"id":"2619468657","title":"Press Release: PTC COMPLETES DIVESTITURE OF KEPWARE AND THINGWORX BUSINESSES","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468657","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468657?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:30","pubTimestamp":1773664200,"startTime":"0","endTime":"0","summary":"-- Divestiture of Kepware Industrial Connectivity and ThingWorx IoT. businesses enables PTC to increase focus on Intelligent Product Lifecycle. repurchases; Announcing $375 million accelerated share repurchase program. BOSTON, March 16, 2026 /PRNewswire/ -- PTC  today announced it has completed the previously announced sale of the company's Kepware industrial connectivity and ThingWorx Internet of Things  businesses to TPG, a leading global alternative asset management firm.\"We are pleased to complete the divestiture of our Kepware and ThingWorx businesses as we increase our focus on our Intelligent Product Lifecycle vision,\" said Neil Barua, President and CEO, PTC. \"We want to thank the teams moving over for their years of service, and we wish them well moving forward.\". PTC received cash proceeds of $523 million upon closing , reflecting closing adjustments of $42 million related to working capital and indebtedness . Net after-tax transaction proceeds will be approximately $375 milli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4232","LU2362540622.SGD","LU1951200564.SGD","LU2506952337.HKD","BK4585","LU1923623000.USD","BK4576","BK4588","LU2477742899.HKD","BK4022","SG9999014005.SGD","SG9999014013.SGD","LU2506952410.USD","BK4554","PTC","SG9999014021.USD","R","LU1721428347.USD","LU2362541273.HKD","LU2362541513.USD","LU1951198990.SGD"],"gpt_icon":0},{"id":"2619645000","title":"Press Release: LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645000","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619645000?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:01","pubTimestamp":1773662460,"startTime":"0","endTime":"0","summary":"NEW YORK, March 16, 2026  -- LifeMD, Inc. , a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition.\"I have spent my career partnering with management teams, boards, and investors to build the financial infrastructure that enables high-growth companies to scale efficiently and create lasting value,\" said Mr. Kavthekar. \"LifeMD is at an inflection point, with a vertically integrated platform, expanding insurance capabilities, and a commitment to AI-driven innovation that can meaningfully improve patient outcomes while driving operating lever","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","HCSG","LFMD","LU0029874061.USD","XLV","BK4581","BK4167","BK4183","LU0128526141.USD","BK4120","TISI","LABU","BK4022","XBI","R","BK4585","BK4232","BK4588"],"gpt_icon":0},{"id":"2619500274","title":"Press Release: Byrna Technologies Appoints Robert Holmes as Vice President of New Product Development and R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2619500274","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619500274?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"ANDOVER, Mass., March 16, 2026  -- Byrna Technologies Inc.  , a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced the appointment of Robert Holmes as Vice President of New Product Development and Research & Development.In this role, Mr. Holmes will lead Byrna's product innovation strategy and engineering efforts, overseeing the development of new technologies and products while advancing the Company's research and development initiatives. He will work closely with Byrna's engineering, manufacturing, and leadership teams to accelerate product development and expand the Company's portfolio of less-lethal personal security solutions.Byrna is a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions. For more information on the Company, please visit the corporate website here or the Company's","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","BYRN","R","BK4232","BK4022"],"gpt_icon":0},{"id":"2619468835","title":"Press Release: Planet Fitness Appoints Harmit Singh to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468835","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468835?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"Mr. Singh is Chief Financial and Growth Officer of the global apparel company, Levi Strauss & Co.Mr. Singh brings more than four decades of global commercial and financial leadership with a track record of driving growth and value creation across iconic consumer and hospitality brands. As Chief Financial and Growth Officer of Levi Strauss & Co., he oversees finance, investor relations, mergers & acquisitions, corporate strategy, store and franchisee expansion among other imperatives, and has played a central role in shaping and executing the company's financial and operational transformation initiatives. This includes leading the organization through its initial public offering in 2019, accelerating both topline and bottom-line growth while expanding the company's store base by about 200 stores over the last five years. He sits on the Sutter Health Board currently and has served on other public company boards over the past decade.\"Planet Fitness has built a highly trusted, accessible b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","BK4022","LU2125909593.SGD","LU0266013472.USD","LU0757428866.USD","BK4232","LEVI","PLNT","LU0053671581.USD","LU0390134368.USD","BK4202","LU2125909247.SGD","LU1815336091.USD","LU1923622614.USD","R","BK4216","LU2211815571.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2619181452","title":"Press Release: Sotera Health Appoints Kenneth D. Krause to the Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2619181452","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619181452?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"CLEVELAND, March 16, 2026  -- Sotera Health Company  , a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today that it has appointed Kenneth D. Krause as a new independent director to its Board of Directors .\"We are excited to welcome Ken to our Board of Directors,\" said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. \"Ken's leadership and proven track record of creating shareholder value as a public company chief financial officer for over 10 years, and his extensive experience in strategy, finance and governance will be tremendous assets as we continue to grow.\". Mr. Mihas has served as a member of the Board since October 2020 and previously served as a member of the board of managers of the Company's predecessor, Sotera Health Topco Parent, L.P., from 2015 until the Company's initial public offering in November 2020.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BK4585","LU2125909916.SGD","BK4121","BK4588","BK4022","LU1923622291.USD","LU0170899867.USD","ROL","LU2125909759.SGD","BK4232","SHC","R"],"gpt_icon":0},{"id":"2619919077","title":"Press Release: NewtekOne, Inc. Declares Dividends on Common Stock and Series B Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919077","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919077?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:33","pubTimestamp":1773408780,"startTime":"0","endTime":"0","summary":"BOCA RATON, Fla., March 13, 2026  -- NewtekOne, Inc.   announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the Company's outstanding common stock. The dividend is payable on April 1, 2026, to shareholders of record as of March 24, 2026.Certain statements in this press release are \"forward-looking statements\" within the meaning of the rules and regulations of the Private Securities Litigation and Reform Act of 1995 are based on the current beliefs and expectations of NewtekOne's management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. See \"Note Regarding Forward-Looking Statements\" and the sections entitled \"Risk Factors\" in our filings with the Securities and Exchange Commission which are available on NewtekOne's website . Any forward-looking statements made by or on behalf of NewtekOne speak only as to the date they are made, and NewtekOne d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","NEWTP","BK4232","NEWT","BK4184","BK4135"],"gpt_icon":0},{"id":"2619192458","title":"Press Release: Duos Technologies Group Executes Definitive Agreement with Hydra Host","url":"https://stock-news.laohu8.com/highlight/detail?id=2619192458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619192458?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:30","pubTimestamp":1773405000,"startTime":"0","endTime":"0","summary":"Contract expected to deliver $50M+ in Annual Revenue and $40M+ in Annual EBITDA. Contract includes additional 4.3MW deployment under new high power EDC model. Duos and its operating subsidiary Duos Edge AI, Inc. have entered into a commercial partnership with Hydra Host to deliver GPU hosting and GPU-as-a-Service solutions at scale. The partnership is fully funded through the Company's recently completed $65 million public offering and hardware financing arrangements already in place, ensuring deployment can commence immediately without reliance on additional equity financing.This contract represents a powerful commercial validation of Duos' High-Power EDC business line, purpose-built to serve AI companies and high-performance compute tenants requiring premium rack space, dedicated high-density powe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4585","BK4587","BK4181","HST","BK4023","R","BK4022","DUOT","BK4551","AI","BK4528","BK4218","BK4588","BK4543","AIYY","BK4097"],"gpt_icon":0},{"id":"2619194151","title":"Press Release: bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath(R) Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194151","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194151?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403200,"startTime":"0","endTime":"0","summary":"Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's high-value CyPath Lung test. Number of CyPath Lung tests performed in 2025 increased by 99% compared to 2024. Orders for CyPath Lung by physicians and clinics rose 67% YoY due to peer-to-peer marketing, positive real-world experiences and growing test awareness. bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2025.--  Record CyPath Lung Revenue and Unit Sales. Revenue from our. noninvasive diagnostic for lung cancer increased 87% over 2024 with the. number of tests performed rising 99% year over year, reflecting growing. clinical utilization and validating the first phase of our. discontinue unprofitable pathology services and reallocate resources to. revenue and a 9% decrease in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Press Release: bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath(R) Lung","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R"],"gpt_icon":0},{"id":"2619719163","title":"Press Release: Bridgemarq Real Estate Services(R) Reports Annual Financial Results and Declares Monthly Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719163","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619719163?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:30","pubTimestamp":1773401400,"startTime":"0","endTime":"0","summary":"TORONTO, March 13, 2026 /CNW/ - Bridgemarq Real Estate Services Inc.   reported its annual consolidated financial results and announced a monthly dividend to holders of the Company's restricted voting shares.-- In 2025, the Company grew its network by more than 470 net real estate. professionals, an increase of 2% while the Canadian industry contracted. million generated in the prior year, due to the inclusion of the. Adjusted Net Earnings, which measures earnings of the business before certain non-cash gains and losses on a fully diluted basis, amounted to $5.0 million in 2025, compared to $7.3 million in 2024. For the quarter, Adjusted Net Earnings amounted to a loss of $1.2 milli","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Bridgemarq Real Estate Services(R) Reports Annual Financial Results and Declares Monthly Dividend","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","BK4022"],"gpt_icon":0},{"id":"2619365199","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619365199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619365199?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399660,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025.Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:. -- In October 2025, the Company received gross proceeds from the exercise of. 170,068 Series F Warrants of approximately $1.4 million.-- Also in October 2025, we were one of five companies to make a formal. presentation at IDWeek in Atlanta at the session entitled New. Antimicrobials in the Pipeline. Presenting on behalf of Acurx were Dr.Michael Silverman, our Medical Director, and Dr. Kevin Garey, Professor. and Chair, University of Houston College of Pharmacy and the Principal. Investigator for microbiology and microbiome aspects of the ibezapolstat. clinical tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4022","BK4563","BK4539","R","BK4139","BK4232","LABU","MAA","BK4215","BK4585","ACXP"],"gpt_icon":0},{"id":"2619993641","title":"Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619993641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619993641?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:00","pubTimestamp":1773399600,"startTime":"0","endTime":"0","summary":"-- Phase 2 interim results suggest treatment with active immunotherapy. ACI-7104 may slow the progression of Parkinson's disease. -- NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants. of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's. disease in H1 2026, and full 24-month data from Part 1 of the Phase 2. funding to the end of Q3 2027 before any potential milestone payments. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting <ALPHA>-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson's disease  further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage.\". Phase 2 VacSYn trial of our ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","CAPS","BK4099","TM","AD","ACIU","BK4588","03160","R","BK4113","BK4023","IND","BK4232","BK4022","BK4132","ACI","BK4585","PD","BK4555","LU1169589451.USD","LU1169590202.USD","BK4104","BK4139"],"gpt_icon":0},{"id":"2619993351","title":"Press Release: Better Home & Finance Holding Company Announces Fourth Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619993351","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619993351?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:00","pubTimestamp":1773399600,"startTime":"0","endTime":"0","summary":"Better exceeds prior guidance on Tinman AI Platform Funded Loan Volume , reiterates guidance, and establishes Q1 2026 outlook. --  In Q4 2025, Funded Loan Volume grew 56% year over year versus industry. growth of 4%, while revenue grew 77% year over year. up 34% quarter-over-quarter, representing more than 40% of Funded Loan. Volume, and exceeding prior guidance of $600 million. 100% month-over-month throughout Q4 in initial rollout to less than 1% of. partners' combined customer base of over 150 million customers. --  Introducing Q1 2026 guidance and reaffirming the previously stated. outlook for Loan Volume and Adjusted EBITDA breakeven. \"The fourth quarter was about positioning the Company for a material ramp in Funded Loan Volume. The early data speaks for itself as we transition from a D2C originator to an AI-native lending platform with rapidly expanding distribution,\" said Vishal Garg, CEO and Founder of Better. \"With the Tinman AI platform and several landmark partnerships scal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4587","BETR","BK4229","BETRW","BK4022","BK4232","TM","BK4551","03160","AIYY","AI","BK4585","BK4555","BK4604","R","BK4543","BK4528","BK4099","BK4023","BK4588"],"gpt_icon":0},{"id":"2618134132","title":"Press Release: Tenable Appoints Dino DiMarino as Chief Revenue Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134132","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:00","pubTimestamp":1773320400,"startTime":"0","endTime":"0","summary":"COLUMBIA, Md., March 12, 2026  -- Tenable Holdings, Inc. , the exposure management company, today announced the appointment of Dino DiMarino as Chief Revenue Officer . DiMarino joins the leadership team to drive Tenable's next phase of hyper-growth. Based in Boston, DiMarino will oversee global sales, partner ecosystems and revenue operations as the company scales to meet surging enterprise demand for exposure management and AI security.\"Dino has a consistent track record for generating sustained momentum and scaling organizations to take advantage of emerging market opportunities,\" said Mark Thurmond, Co-CEO of Tenable. \"With Dino at the helm, we'll be able to expand our global footprint and accelerate pipeline growth with customers seeking to deepen their AI exposure management programs. We have ambitious goals, and Dino's leadership will be pivotal in driving aggressive expansion, scale and growth.\". \"Tenable is uniquely positioned to help organizations understand and reduce cyber r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","TENB","R","BK4097","LU2286300806.USD","BK4022"],"gpt_icon":0},{"id":"2618113223","title":"Press Release: MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113223","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618113223?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:31","pubTimestamp":1773318660,"startTime":"0","endTime":"0","summary":"Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI Platform Contract | Launch of B cell Llama Nanobody Discovery Platform. MindWalk Holdings Corp. , a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time.\"This quarter, MindWalk reported its third consecutive year-over-year revenue increase and advanced three pipeline programs toward data readouts. US revenue doubled year over year, reflecting our deliberate, strategic focus on North America, including the establishment of biologics services operations in the Boston and Cambridge area and ongoing commercial investment in that market. Recently, our largest enterprise AI client signed a one-year LensAI platform contract, the first of its kind for us. LensAI is actively being rolled out a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","TM","BK4551","HYFT","AIYY","BK4587","BK4585","BK4604","03160","BK4232","BK4528","AI","BK4121","BK4588","BK4555","BK4022","BK4543","BK4099","R"],"gpt_icon":0},{"id":"2618713124","title":"Press Release: Integer Appoints James Flanagan and Aaron Kapito to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618713124","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618713124?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"\"Irenic invested in Integer because we believe the Company is well positioned to capitalize on attractive growth opportunities in key markets and leverage its strong industry relationships,\" said Adam Katz, Co-Founder and Chief Investment Officer of Irenic Capital Management. \"The appointment of these highly accomplished directors will further enhance Integer's focus on growth and value creation. We appreciate our collaborative engagement with Integer.\". Mr. Flanagan is the former Chief Operating Officer of PwC from 2014 to 2021, bringing proven diversified, strategic, operational and qualified financial expertise through 39 years of increasing client and management roles. Previously, he also served as PwC's US Financial Services Practice Leader from 2006 to 2014, and prior to that as the Transaction Services Leader from 2001 to 2006 and Transaction Services Partner from 1994 to 2001. He has served on the Board of Directors at Belami","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LU1815336091.USD","LU1169589451.USD","ITGR","LU0757428866.USD","R","LU0029874061.USD","CDMO","BK4082","LU0128526141.USD","LU0566484027.USD","BK4139","BK4022","LU1169590202.USD","LU1559883803.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}